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waBACKGROUND Neuron-speciﬁc enolase (NSE) is a widely-used biomarker for prognostication of neurological outcome
after cardiac arrest, but the relevance of recommended cutoff values has been questioned due to the lack of a stan-
dardized methodology and uncertainties over the inﬂuence of temperature management.
OBJECTIVES This study investigated the role of NSE as a prognostic marker of outcome after out-of-hospital cardiac
arrest (OHCA) in a contemporary setting.
METHODS A total of 686 patients hospitalized after OHCA were randomized to targeted temperature management at
either 33C or 36C. NSE levels were assessed in blood samples obtained 24, 48, and 72 h after return of spontaneous
circulation. The primary outcome was neurological outcome at 6 months using the cerebral performance category score.
RESULTS NSE was a robust predictor of neurological outcome in a baseline variable-adjusted model, and target tem-
perature did not signiﬁcantly affect NSE values. Median NSE values were 18 ng/ml versus 35 ng/ml, 15 ng/ml versus
61 ng/ml, and 12 ng/ml versus 54 ng/ml for good versus poor outcome at 24, 48, and 72 h, respectively (p < 0.001). At
48 and 72 h, NSE predicted neurological outcome with areas under the receiver-operating curve of 0.85 and 0.86,
respectively. High NSE cutoff values with false positive rates #5% and tight 95% conﬁdence intervals were able to
reliably predict outcome.
CONCLUSIONS High, serial NSE values are strong predictors of poor outcome after OHCA. Targeted temperature
management at 33C or 36C does not signiﬁcantly affect NSE levels. (Target Temperature Management After Cardiac
Arrest [TTM]; NCT01020916) (J Am Coll Cardiol 2015;65:2104–14) © 2015 by the American College of Cardiology
Foundation.m the *Department of Anesthesia and Intensive Care, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg;
ompetence Centre for Methodology and Statistics, Luxembourg Institute of Health, Luxembourg, Luxembourg; zDepartment of
rdiology B, The Heart Centre, Rigshospitalet University Hospital, Copenhagen, Denmark; xDepartment of Intensive Care,
iversity Hospital of Wales, Cardiff, United Kingdom; kDepartment of Anesthesia and Intensive Care, Oslo University Hospital,
shospitalet, Oslo, Norway; {Department of Intensive Care, Liverpool Hospital, Sydney, Australia; #Department of Intensive
re, Academic Medical Centrum, Amsterdam, the Netherlands; **Laboratory of Cardiovascular Research, Luxembourg Institute
Health, Luxembourg, Luxembourg; yyDepartment of Cardiology, Skåne University Hospital, Lund, Sweden; zzDepartment of
ensive Care, Geneva University Hospital, Geneva, Switzerland; xxDepartment of Cardiothoracic Anesthesiology RT, The Heart
ntre, Rigshospitalet University Hospital, Copenhagen, Denmark; kkDepartment of Clinical Sciences, Division of Neurology,
nd University, Lund, Sweden; {{Department of Anesthesia and Intensive Care, Skåne University Hospital, Lund University,
nd, Sweden; ##Copenhagen Trial Unit, Centre of Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark;
Department of Intensive Care, Santa Maria degli Angeli, Pordenone, Italy; yyyDepartment of Intensive Care, Leeu-
rden Medical Centrum, Leeuwarden, the Netherlands; zzzDepartment of Clinical Biology, Centre Hospitalier de Luxembourg,
J A C C V O L . 6 5 , N O . 1 9 , 2 0 1 5 Stammet et al.
M A Y 1 9 , 2 0 1 5 : 2 1 0 4 – 1 4 NSE for Prognostication After Cardiac Arrest
2105AB BR E V I A T I O N S
AND ACRONYM S
CPC = cerebral performance
category
FPR = false positive rate
ICU = intensive care unit
IDI = integrated discrimination
improvement
NRI = net reclassiﬁcation index
NSE = neuron-speciﬁc enolase
OHCA = out-of-hospital
cardiac arrestC omatose patients admitted to an intensivecare unit (ICU) after an out-of-hospital car-diac arrest (OHCA) have a mortality rate
of around 50%. In the majority of cases, initial
ICU mortality is driven by hemodynamic fail-
ure, whereas later morbidity and mortality are due
to brain damage (1). A large proportion of patients
die of withdrawal of life-sustaining therapies because
of presumed poor prognosis (2,3). Thus, adequate
prognostication tools for neurological outcome pre-
diction are crucial for therapeutic guidance in this
severely ill population.SEE PAGE 2115 ROSC = return of spontaneous
circulationBiomarkers of brain damage, particularly neuron-
speciﬁc enolase (NSE), have been widely studied
as markers for outcome prognostication (4,5). The
protein NSE is a 78kDa glycolytic enzyme involved in
glucose metabolism and is mainly found in neuronal
and neuroendocrine cells. Its half-life is approxi-
mately 24 h. Previous studies on patients not treated
with hypothermia after cardiac arrest suggested a
cutoff level of 33 ng/ml at 48 h to be predictive of
death and poor neurological function (6); the Amer-
ican Academy of Neurology subsequently adopted
this cutoff into prognostication guidelines (7). With
the implementation of induced hypothermia and its
assumed neuroprotective effect, the validity of this
cutoff has been questioned. Subsequent studies
yielded conﬂicting results, probably due to method-
ological issues and the lack of standardization of
dosing methods (8). Consequently, current guidelines
do not advocate NSE for outcome prediction (9), and a
recent advisory statement suggests a cautious use of
“high NSE levels” within a multimodal prognostica-
tion algorithm (10).
In this context of uncertainty, the TTM trial (Target
Temperature Management After Out-of-Hospital
Cardiac Arrest) (11), a multicenter clinical trial thatLuxembourg, Luxembourg; and the xxxDepartment of Anesthesia and Intensi
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temperature management of 33C or 36C,
provided a platform to investigate the role of
NSE as a prognostic marker of outcome after
OHCA in a contemporary setting.
METHODS
All patients included in this study were part of
the TTM trial (November 2010 to July 2013)
comparing 2 temperature regimens in uncon-
scious adult patients admitted to an ICU after
an OHCA of a presumed cardiac cause. The
TTM trial design, the statistical analysis plan,
and the main results have been published
previously (11–13). The randomizationwas stratiﬁed by
site and performed centrally with adequate allocation
concealment and sequence generation. A target tem-
perature of 33C or 36C was initiated in each group
according to allocation. At 28 h after start of the
intervention, rewarming to 37C was commenced at a
maximum speed of 0.5C/h. This pre-deﬁned substudy
of the TTM trial on NSE was approved by the steering
committee before starting NSE analysis.
The TTM trial protocol was approved by ethical
committees in each participating country, and in-
formed consent was waived or obtained from all
participants or relatives according to national legis-
lations, in line with the Helsinki declaration (14).
Serum blood samples were taken from the patients
at 24, 48, and 72 h after return of spontaneous circu-
lation (ROSC). All samples were pre-analytically pro-
cessed at the different sites, aliquoted, and frozen
to 80C before shipment to the Integrated BioBank
of Luxembourg before analysis. NSE values were not
available to the treating physicians during the trial.
NSE analyses were performed 6 months after trial
completion at the clinical biology laboratory of the
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FIGURE 1 Study Flow Charts
Patients with samples (n=700)
Patients included (n=686)
Included in TTM trial (n=939)
No analysis possible (n=14):
Dead before first sample possible (n=6)
Insufficient sample volume (n=2)
No outcome measurement (n=5)
Incorrect identification of sample (n=1)
Patients from centers not participating
in blood sampling (n=239)
CPC 1-2
(n=174)
CPC 3-5
(n=170)
TTM 33°C (n=344) TTM 36°C (n=342)
CPC 1-2
(n=174)
CPC 3-5
(n=168)
2,058 potential
samples
Hemolysis
(n=24 samples)
Patients dying
within 72 hours
(n=62 samples)
Insufficient volume, no
sample drawn, empty
vials,...
(n=149 samples)
1,823 samples
B
A
♦
♦
♦
♦
(A) This ﬂow chart illustrates the number of patients enrolled in the TTM trial and included in this substudy; (B) the accompanying chart
provides reasons for eliminating serum samples from analysis. CPC ¼ cerebral performance category; TTM ¼ target temperature management.
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2106were tested for hemolysis using the Roche hemolysis
index with measurements at 600 and 570 nm.
Because of measurement interference, all samples
with a positive hemolysis index ($500 mg/l of
hemoglobin) were discarded.
Determination of NSEwas performed using a COBAS
e601 line with an Electro-Chemi-Luminescent-
Immuno-Assay (ECLIA) kit (Roche Diagnostics, Rotk-
reuz, Switzerland). The measuring range extended
from 0.05 to 370 ng/ml. Samples with values above the
measuring range had to be diluted accordingly. Func-
tional sensitivity was at 0.25 ng/ml, and expected
normal values were <17.0 ng/ml. In our laboratory,between-run precision at concentrations of 10.5 and
83.3 ng/ml was 6.8% and 5.7%, respectively.
Neurological prognostication as well as withdrawal
of life-supporting therapies were standardized and
reported according to the trial protocol (12,13,15).
We aimed to investigate NSE as a predictor of death
and cerebral performance after OHCA in 2 targeted
temperature groups as well as in a pooled sample. We
studied the inﬂuence of the targeted temperature,
evolution over time, predictive power of NSE, and
cutoff values, including a multivariable analysis. We
deﬁned high NSE cutoff values as having a false
positive rate of #5%.
TABLE 1 Main Demographic and Utstein Data
33C Group
(n ¼ 344)
36C Group
(n ¼ 342)
p
Value*
Age, yrs 64  12 63  13 0.53
Male 292 (83) 273 (79) 0.18
Bystander CPR performed 255 (72) 249 (72) 0.91
First monitored rhythm
VF or nonperfusing VT 273 (79) 272 (80)
Asystole or PEA 67 (19) 64 (19)
ROSC after bystander
deﬁbrillation
6 (2) 3 (1) 0.68†
Time from CA to ROSC, min 30  22 31  24 0.85
Initial serum lactate levels,
mmol/l
7  4 7  4 0.93
Circulatory shock on admission 45 (13) 43 (12) 0.97
Values are mean  SD or n (%). *Wilcoxon rank sum test for continuous variables
and chi-square test for categorical variables. †Fisher exact test.
CA ¼ cardiac arrest; CPR ¼ cardiopulmonary resuscitation; PEA ¼ pulseless
electric activity; ROSC ¼ return of spontaneous circulation; VF ¼ ventricular
ﬁbrillation; VT ¼ ventricular tachycardia.
FIGURE 2 NSE Time Course
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In these boxplots of neuron-speciﬁc enolase (NSE) over the ﬁrst
72 h after return of spontaneous circulation (ROSC), data are
represented as median, quartile 1, quartile 3, and lower fence
(i.e., lowest value above quartile 1  1.5 [quartile 3 – quartile 1])
and upper fence (i.e., greater value below quartile 3 þ 1.5
[quartile 3 – quartile 1]). No statistical differences were found in
NSE values between temperature groups (at all 3 time points,
lowest p values were 0.46 in the poor outcome group and 0.09
in the good outcome group). CPC ¼ cerebral performance
category.
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2107The primary outcome in this study was neurolog-
ical function at 6 months, dichotomized to good or
poor outcome according to the Cerebral Performance
Category (CPC) scale (16). The CPC score classiﬁes
patients into 5 categories: CPC 1 (no neurological
disability); CPC 2 (minor neurological deﬁcit); CPC 3
(severe neurological impairment, dependent in
everyday life); CPC 4 (coma); and CPC 5 (brain death).
Secondary outcomes were an assessment of dis-
ability according to modiﬁed Rankin scale (mRS) at
6 months and all-cause mortality at the end of the
trial. Scores on the mRS range from 0 to 6, with
0 representing no symptoms, 1 no clinically sig-
niﬁcant disability, 2 slight disability, 3 moderate
disability, 4 moderately severe disability, 5 severe
disability, and 6 death.
CPC scores 1 or 2 and mRS 0 to 3 were considered a
good outcome, whereas CPC 3 to 5 and mRS 4 to 6
were considered a poor outcome.
STATISTICAL ANALYSIS. Comparisons of patients’
clinical characteristics between temperature groups
were performed using the Wilcoxon rank sum test
for continuous variables and chi-square or Fisher
exact test for categorical variables. Medians with
interquartile range (IQR) and mean  SD are
presented.
Changes of NSE concentrations over time were
tested for signiﬁcance using the Wilcoxon signed rank
test. Comparison of NSE distribution between CPC
groups was performed with the Wilcoxon rank sum
test.
At each time point, receiver-operating character-
istic curves were plotted and corresponding areasunder the curve (AUCs) were determined to eval-
uate the predictive power of NSE on CPC. Cutoffs
were provided as a compromise between sensitivity
and speciﬁcity by maximizing the Youden index,
as deﬁned by sensitivity þ speciﬁcity – 100%, and
by providing 95% to 100% speciﬁcity. The same
analyses were then performed on NSE change from
24 to 48 h and from 48 to 72 h. All sensitivity
and speciﬁcity values were corrected for optimism
using bootstrap internal validation (100-fold) to
avoid overﬁtting (17). When possible, the normal
approximation was used to obtain conﬁdence in-
tervals (CIs); otherwise, the Wilson formula was
used (18).
Finally, NSE at 24, 48, and 72 h were added to
a clinical multivariable logistic model containing
temperature allocation, age, sex, bystander cardio-
pulmonary resuscitation, ﬁrst monitored rhythm,
time from cardiac arrest to ROSC, lactate levels,
and circulatory shock on admission. The relation-
ship between NSE and CPC was supposed to be
linear; Pearson residuals were plotted and did not
reveal any strong pattern. Restricted cubic splines
were also used to model the nonlinear relationship
TABLE 2 NSE Cutoff Values
Cutoff (ng/ml) Sensitivity 95% CI Speciﬁcity 95% CI
Pooled
NSE Youden 27 0.60 0.55–0.65 0.76 0.71–0.80
NSE 5 49 0.33 0.28–0.38 0.95 0.93–0.97
NSE 4 54 0.29 0.24–0.34 0.96 0.94–0.98
24 h NSE 3 61 0.24 0.19–0.28 0.97 0.95–0.99
NSE 2 66 0.21 0.16–0.25 0.98 0.97–1.00
NSE 1 76 0.15 0.11–0.19 0.99 0.97–1.00
NSE 0 107 0.09 0.06–0.12 1.00 0.99–1.00
NSE Youden 29 0.69 0.64–0.75 0.87 0.83–0.91
NSE 5 42 0.61 0.55–0.67 0.95 0.92–0.97
NSE 4 46 0.60 0.55–0.66 0.96 0.94–0.98
48 h NSE 3 46 0.59 0.53–0.64 0.97 0.95–0.99
NSE 2 48 0.58 0.52–0.64 0.98 0.96–0.99
NSE 1 68 0.47 0.42–0.53 0.99 0.97–0.97
NSE 0 120 0.27 0.22–0.32 1.00 0.99–1.00
NSE Youden 23 0.70 0.64–0.76 0.88 0.85–0.92
NSE 5 33 0.63 0.57–0.69 0.95 0.92–0.97
NSE 4 35 0.62 0.56–0.68 0.96 0.93–0.98
72 h NSE 3 35 0.63 0.57–0.68 0.97 0.95–0.99
NSE 2 38 0.58 0.52–0.64 0.98 0.96–0.99
NSE 1 45 0.54 0.48–0.60 0.99 0.97–1.00
NSE 0 50 0.52 0.46–0.58 1.00 0.99–1.00
33C
NSE Youden 27 0.60 0.52–0.67 0.73 0.66–0.79
NSE 5 49 0.31 0.24–0.39 0.95 0.91–0.98
NSE 4 54 0.27 0.20–0.34 0.96 0.93–0.99
24 h NSE 3 61 0.22 0.15–0.28 0.97 0.94–0.99
NSE 2 68 0.19 0.13–0.25 0.98 0.95–1.00
NSE 1 96 0.11 0.06–0.16 0.99 0.96–1.00
NSE 0 103 0.11 0.06–0.16 1.00 0.97–1.00
NSE Youden 33 0.64 0.56–0.71 0.90 0.86–0.95
NSE 5 46 0.58 0.50–0.65 0.95 0.92–0.98
NSE 4 46 0.58 0.50–0.66 0.96 0.93–0.99
48 h NSE 3 48 0.57 0.49–0.65 0.97 0.93–0.99
NSE 2 48 0.56 0.48–0.64 0.98 0.95–1.00
NSE 1 52 0.54 0.46–0.62 0.99 0.96–1.00
NSE 0 120 0.25 0.18–0.32 1.00 0.97–1.00
NSE Youden 26 0.69 0.62–0.77 0.91 0.86–0.95
NSE 5 33 0.65 0.57–0.73 0.95 0.91–0.98
NSE 4 35 0.63 0.55–0.71 0.96 0.93–0.99
72 h NSE 3 35 0.63 0.55–0.71 0.97 0.93–0.99
NSE 2 41 0.58 0.50–0.66 0.98 0.96–1.00
NSE 1 45 0.53 0.45–0.61 0.99 0.96–1.00
NSE 0 48 0.54 0.45–0.62 1.00 0.97–1.00
Continued on the next page
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2108between NSE and CPC, but the ﬁndings were not
markedly different (data not shown). The additional
predictive power brought by NSE to these markers
was evaluated by computing the continuous net
reclassiﬁcation index (NRI) and the integrated
discrimination improvement (IDI) (19). In the
multivariable analysis, missing values were
accounted for using 10-fold multiple imputations.Computations were performed using the R soft-
ware, version 2.15.2, packages ROCR, pROC, Hmisc,
and rms (R Foundation for Statistical Computing,
Wien, Austria). A p value <0.05 was considered to
indicate statistical signiﬁcance.
RESULTS
The TTM trial investigated 939 patients with no dif-
ference in mortality or neurological function between
the 33C and 36C groups (11). Overall, 700 consecu-
tive patients from 29 different sites participated in
the biomarker substudy (Figure 1A). A total of 1,823
serum samples from 686 different patients were
analyzed (Figure 1B).
Main patient characteristics are shown in Table 1.
There were no signiﬁcant differences between our
study population and the main TTM trial population
or in neurological outcome between temperature
groups (p ¼ 0.90) (Figure 1A).
Median NSE values were 18 ng/ml (IQR: 12 to
27 ng/ml) versus 35 ng/ml (IQR: 21 to 58 ng/ml), 15 ng/ml
(IQR: 10 to 2 ng/ml 1) versus 61 ng/ml (IQR: 24 to
125 ng/ml), and 12 ng/ml (IQR: 9 to 16 ng/ml) versus
54 ng/ml (IQR: 19 to 132 ng/ml) for good versus poor
outcome at 24, 48, and 72 h, respectively (p < 0.001).
NSE values in both temperature groups were higher in
the poor versus the good outcome group at each time
point (Figure 2). In both good and poor outcome groups,
levels of NSE were not signiﬁcantly affected by the
target temperature level.
In the poor outcome groups, we observed a sig-
niﬁcant increase of median NSE values between 24
and 48 h in both temperature groups: from 35 ng/ml
(IQR: 21 to 56 ng/ml) to 60 ng/ml (IQR: 22 to 119 ng/ml)
in 33C (p < 0.001) and from 34 ng/ml (IQR: 21 to
62 ng/ml) to 66 ng/ml (IQR: 24 to 137 ng/ml) in 36C
(p < 0.001). Between 48 and 72 h, median NSE values
decreased in the 33C group from 60 ng/ml (IQR: 22
to 119 ng/ml) to 52 ng/ml (IQR: 20 to 147 ng/ml)
(p ¼ 0.029) and in the 36C group from 66 ng/ml (IQR:
24 to 137 ng/ml) to 56 ng/ml (IQR: 19 to 123 ng/ml)
(p ¼ 0.75).
In the good outcome groups, we detected a sig-
niﬁcant decrease of approximately 3 to 4 ng/ml be-
tween 2 consecutive time points, with median NSE
values at 24, 48, and 72 h at 33C of 18 ng/ml (IQR: 12
to 27 ng/ml), 15 ng/ml (IQR: 11 to 22 ng/ml), 13 ng/ml
(IQR: 9 to 18 ng/ml), respectively (p < 0.001), and at
36C of 18 ng/ml (IQR: 12 to 26 ng/ml), 14 ng/ml (IQR:
10 to 20 ng/ml), 11 ng/ml (IQR: 8 to 15 ng/ml),
respectively (p < 0.001).
The capacity of NSE to predict CPC at 6 months
was ﬁrst determined using receiver-operating
TABLE 2 Continued
Cutoff (ng/ml) Sensitivity 95% CI Speciﬁcity 95% CI
36C
NSE Youden 23 0.66 0.59–0.74 0.71 0.63–0.78
NSE 5 50 0.36 0.29–0.44 0.95 0.91–0.98
NSE 4 57 0.30 0.23–0.37 0.96 0.93–0.99
24 h NSE 3 57 0.28 0.21–0.35 0.96 0.93–0.99
NSE 2 65 0.23 0.16–0.30 0.98 0.95–1.00
NSE 1 76 0.16 0.10–0.21 0.99 0.96–1.00
NSE 0 108 0.08 0.03–0.12 1.00 0.97–1.00
NSE Youden 29 0.70 0.63–0.78 0.90 0.85–0.95
NSE 5 40 0.61 0.53–0.69 0.95 0.91–0.98
NSE 4 42 0.62 0.54–0.70 0.96 0.93–0.99
48 h NSE 3 44 0.61 0.53–0.69 0.97 0.93–0.99
NSE 2 44 0.60 0.52–0.68 0.98 0.96–1.00
NSE 1 70 0.48 0.40–0.57 0.99 0.96–1.00
NSE 0 76 0.45 0.37–0.53 1.00 0.97–1.00
NSE Youden 22 0.68 0.60–0.76 0.89 0.84–0.94
NSE 5 34 0.61 0.52–0.70 0.95 0.91–0.98
NSE 4 34 0.62 0.53–0.70 0.96 0.93–0.99
72 h NSE 3 37 0.59 0.50–0.67 0.97 0.93–0.99
NSE 2 37 0.58 0.49–0.67 0.98 0.95–1.00
NSE 1 48 0.51 0.43–0.60 0.99 0.96–1.00
NSE 0 53 0.52 0.43–0.61 1.00 0.97–1.00
NSE Youden indicates an NSE cutoff that compromises sensitivity and speciﬁcity (maximized Youden index). The
number following NSE refers to the false positive rate. Sensitivity and speciﬁcity are corrected by bootstrap
internal validation.
CI ¼ conﬁdence interval; NSE ¼ neuron-speciﬁc enolase.
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2109characteristic curves (Figures 3A to 3C). Twenty-four
hours after cardiac arrest, NSE predicted 6-month
CPC with an AUC of 0.75. At 48 and 72 h, AUCs were
0.85 and 0.86, respectively. The AUCs obtained at
33C and 36C groups were similar.
The change of NSE between 24 and 48 h had an
AUC of 0.80 (33C group) and 0.84 (36C group), and
between 48 and 72 h, the AUC was lower than 0.70 for
both groups. An increase of NSE of 6 ng/ml between
any of the time points, regardless of the target tem-
perature, was also predictive of a poor outcome
(speciﬁcity 94% and sensitivity 64% between 24 and
48 h; speciﬁcity 93% and sensitivity 39% between 48
and 72 h).
In our cohort, the previously recommended (7)
cutoff value of 33 ng/ml at 48 h yielded a speciﬁcity
of 0.91 and a sensitivity of 0.65.
By maximizing the Youden index, cutoff values for
NSE in the pooled patient group were 27, 29, and
23 ng/ml at 24, 48, and 72 h, respectively (Table 2).
NSE cutoff values with false positive rates (FPRs)
from 5 to 1 range from 49 to 76 ng/ml, 42 to 68 ng/ml,
and 33 to 45 ng/ml at 24, 48, and 72 h, respectively
(Table 2). No patient with a good outcome had an
NSE value at or above the cutoff reported with an
FPR of zero (“NSE 0” values in Table 2).
Kaplan-Meier curves showed that survival was
signiﬁcantly lower in groups with higher NSE levels as
deﬁned by quartiles (Central Illustration). NSE at each
time point was an efﬁcient predictor of survival in
both temperature groups (all p < 0.05).
MULTIVARIABLE ANALYSIS. In multivariable anal-
ysis including serial NSE, target temperature, and
baseline variables (age, sex, bystander cardiopulmo-
nary resuscitation, ﬁrst monitored rhythm, time to
ROSC, lactate levels on admission, and circulatory
shock), NSE was a strong predictor of neurological
outcome at each time point (Table 3). Our model inte-
grating NSE measures at 3 time points had a speciﬁcity
of 0.88 and a sensitivity of 0.84. Continuous NRI
(1.29; p < 0.001) and IDI (0.37; p < 0.001) showed that
NSE signiﬁcantly improved classiﬁcation compared
with a model with clinical parameters alone. When
modeling CPC using the mean and the trend effects
of NSE values, which are independent, we found
the same results. When adjusted for centers, NSE
remained a highly signiﬁcant outcome predictor, and
no site effect was observed (data not shown).
When analyzing the capacity of NSE to predict mRS
and death at 6 months as well as death at the end of
the trial, we found similar results to those referring to
CPC at 6 months and with no inﬂuence of target
temperature (data not shown).DISCUSSION
In a large international trial of patients treated with
targeted temperature after out-of-hospital cardiac
arrest, NSE was a strong and robust predictor of
outcome (Central Illustration). Target temperature
level did not signiﬁcantly inﬂuence NSE values.
Although median NSE values declined between 48
and 72 h in all groups, we conﬁrmed that an increase
of NSE between any 2 time points was associated with
poor outcome (20–24). There was no signiﬁcant dif-
ference between temperature groups at any time
point for any of our outcome measures, substantiat-
ing previous studies reporting no statistically signif-
icant differences in NSE values between temperatures
(21,25–27). Other studies reporting lower NSE values
in 33C-treated patients suffered from limitations,
notably due to the comparison of patients treated at
33C to historical control subjects (28) or to a small
sample size in a population without fever manage-
ment in the control group (20).
The cut-off values at 48 and 72 h after ROSC
provided the best capacity to predict outcome
when referring to the highest sensitivities and
speciﬁcities. At 24 h, sensitivity was too low to be
FIGURE 3 NSE Receiver-Operating Curves
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Receiver-operating characteristic curves with areas under the curve (AUCs) for NSE at (A) 24, (B) 48, and (C) 72 h after ROSC for outcome
prediction according to CPC at 6 months. Abbreviations as in Figure 2.
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2110of clinical interest. Deliberately, we presented FPRs
of 5% or lower, as no compromise in the literature
exists that deﬁnes the absolute best characteristics
of a biomarker cutoff value. As such, we showed
that “high” NSE cutoff values (with #5% FPR and
tight 95% CIs) offer reliable prediction of poor
outcome with sufﬁcient sensitivity to remain clin-
ically useful within a multimodal prognostication
package, including clinical examination, imaging,
neurophysiology, and biomarkers (10,29). Notwith-
standing the low FPR and narrow 95% CIs of cut-
off values in our sample, no single test, even
with high speciﬁcity, should be considered forwithdrawal of life-sustaining therapies. Also, by
looking for cutoffs with an FPR of 0, indicating
absolute poor outcome prediction, values around
100 ng/ml might have a too low sensitivity to be of
clinical utility.
Our cutoff values are higher than the formerly
reported 33 ng/ml at 48 h (6,7). Several explana-
tions exist for discrepancies with previous studies.
First, the assay we used differed from some of the
previous reports, and variability among NSE assays
is well described (30). A recent publication by
Rundgren et al. (8) showed that NSE values can
vary by 15% to 36% based on the assay used and
CENTRAL ILLUSTRATION NSE for Prognostication After Cardiac Arrest
Stammet, P. et al. J Am Coll Cardiol. 2015; 65(19):2104–14.
After an out-of-hospital cardiac arrest (OHCA), neuron-speciﬁc enolase (NSE) is released by dying neurons into the blood stream. NSE values determined in blood
samples taken at 24, 48, and 72 h after cardiac arrest can guide prognostication after OHCA. No signiﬁcant difference between target temperature groups was noticed in
NSE levels. When taken at these time points, NSE levels, divided into quartiles, showed that survival was signiﬁcantly lower with higher NSE levels as seen in the Kaplan-
Meier curves of pooled data from both target temperature groups.
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TABLE 3 Multivariable Analysis With NSE and Clinical Variables
Effect
Odds
Ratio
95% CI
p
ValueLower Upper
Intercept 6.853 0.001 0.0001 0.001 <0.0001
NSE 24 h, ng/ml 0.034 0.966 0.945 0.989 0.0034
NSE 48 h, ng/ml 0.040 1.041 1.012 1.070 0.0044
NSE 72 h, ng/ml 0.066 1.069 1.033 1.105 0.0001
Target temperature 0.247 1.280 0.796 2.059 0.3076
Age, yrs 0.094 1.098 1.073 1.124 <0.0001
Male 0.307 0.735 0.408 1.326 0.3066
Bystander CPR
performed
0.601 0.548 0.323 0.930 0.0257
First monitored rhythm 1.276 0.279 0.134 0.580 0.0006
ROSC after bystander
deﬁbrillation
1.460 0.232 0.038 1.421 0.1142
Time from CA to ROSC 0.010 1.010 0.996 1.023 0.1534
Serum lactate level 0.012 1.012 0.950 1.078 0.7051
Shock on admission 0.332 1.394 0.661 2.939 0.3829
Abbreviations as in Tables 1 and 2.
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Outcome measurements in previous publications
also differed in time to follow-up, ranging from ICU
discharge to 6 months, and some studies catego-
rized neurological outcome differently (5). We used
the most common follow-up period of 6 months,
the CPC 1 or 2 score for good outcome, the CPC 3 to
5 scores for poor outcome, and, most importantly, a
blinded outcome assessment with face-to-face in-
terviews (11,12,31,32). Another explanation for our
reported discrepancies might be that the TTM trial
prognostication and, when indicated, subsequent
withdrawal of life-sustaining therapy were well
codiﬁed and delayed. Furthermore, our sample
included more than twice the number of patients
compared with the 272 normothermic individuals in
the PROPAC (PROgnosis after PostAnoxic Coma)
trial (6). The latter served as a basis of the American
Academy of Neurology guidelines for outcome pre-
diction, which ﬁxed the NSE cutoff as 33 ng/ml with an
FPR of 0 (7). In our cohort, an FPR of 0 could not be
veriﬁed at the 33 ng/ml cutoff, which yielded an FPR of
9%. Zellner et al. (33) had similar ﬁndings as ours in
patients at 33C with 10% FPR at cutoff values of 41 ng/ml
at 48 h.
Our multivariable model, integrating NSE at the 3
time points, conﬁrmed NSE as a predictor of CPC in
this set of patients as shown by the highly signiﬁcant
NRI and IDI. These ﬁndings are in line with previous
studies and strengthen the position of NSE as a robust
and clinically-useful outcome predictor (21).
STUDY STRENGTHS AND LIMITATIONS. Although
being a pre-deﬁned substudy of the TTM trial, not all
sites enrolling in the main trial participated inbiomarker sampling. However, as the trial was strat-
iﬁed for sites, the balanced design tends to be pre-
served in all comparisons between the temperature
groups. Indeed, our population did not differ signiﬁ-
cantly from the TTM trial population. Not all patients
had blood samples taken at every time point, and
there was no external quality control at each partici-
pating site where samples were collected and pre-
analytically processed.
Biomarkers, unlike some prognostic neurophysi-
ology tests, are unaltered by sedation and may,
therefore, be a more objective marker of brain injury.
One general limitation of biomarkers is that their
measurement is punctual, whereas production or
secretion is a dynamic process, highlighting the
importance of serial measurements taking into ac-
count the absolute values, their changes over time,
and serial cutoffs to best predict outcome (4). Brain
biomarkers measured in circulating blood might have
some additional weaknesses as the integrity of the
blood brain barrier after ischemia-reperfusion injury
in individuals cannot be measured and may vary
substantially. In the case of NSE, which is predomi-
nantly released from neural and neuroendocrine
cells, caution is warranted as serum levels might
reﬂect variable degrees of brain damage, disruption of
the blood brain barrier, or—albeit rarely—NSE from
extracerebral origins as seen in small-cell lung cancer
and neuroendocrine tumors (24).
The major strength of this investigation is that it
was a pre-deﬁned substudy investigating a serum
biomarker for prognostication after OHCA within the
largest multicenter randomized clinical trial studying
2 target temperature regimens in comatose cardiac
arrest patients. It represents the largest prospective
study of its kind. All analyses were performed in a
single core laboratory, limiting the inﬂuence of assay
variability and laboratory processing. The results of
NSE values were not available to the treating physi-
cians during the trial and, therefore, did not inﬂu-
ence prognostication of patients, reducing the risk of
“self-fulﬁlling prophecy.” A unique feature of the
TTM trial is that prognostication and withdrawal
were standardized, which increases the validity of
our results (34).
As is the case with other prognostic tools, the
current study demonstrated that the functional con-
sequences of brain injury cannot be predicted by NSE
alone. When using NSE, we recommend a dynamic
approach with serial measurements within a prog-
nostication protocol including other methods, such
as clinical examination, electroencephalogram, brain
imaging, and somatosensory-evoked potentials, for
the most accurate outcome prediction (10,29).
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Cardiac arrest
is associated with 50% mortality in those patients admitted
to hospital after resuscitation in the ﬁeld, and the predomi-
nant cause of death in these cases is severe neurological
injury.
COMPETENCY IN PATIENT CARE: Consistently high levels of
brain-oriented biomarkers, like NSE, may identify patients prone
to poor outcomes after resuscitation from OHCA.
TRANSLATIONAL OUTLOOK: Identiﬁcation of combina-
tions of variables that accurately correlate with more or
less favorable outcomes could lead to the development
of more effective therapeutic strategies for victims of
cardiac arrest.
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2113CONCLUSIONS
Serial, high NSE values have a high predictive value of
poor outcome in comatose out-of-hospital cardiac
arrest patients. This predictive value of NSE is not
signiﬁcantly affected by target temperature at either
33C or 36C.
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